Emerging Trends in Minimally Invasive Glaucoma Surgery (MIGS) Devices Market
The Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market was valued at $144 million in 2016, and is expected to reach $912 million by 2023, registering a CAGR of 30.1% from 2017 to 2023.
The Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market was valued at $144 million in 2016, and is expected to reach $912 million by 2023, registering a CAGR of 30.1% from 2017 to 2023.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Opportunity Analysis and Industry Forecast, 2016-2023
Introductionof<br />
<strong>MIGS</strong> <strong>Devices</strong> <strong>Market</strong><br />
The global m<strong>in</strong>imally <strong>in</strong>vasive glaucoma surgery (<strong>MIGS</strong>) devices market was valued at<br />
$144 million <strong>in</strong> 2016, and is projected to reach $912 million by 2023, grow<strong>in</strong>g at a<br />
CAGR of 30.1% from 2017 to 2023. The glaucoma <strong>in</strong> conjunction with cataract surgery<br />
segment accounted for three-fifths share of the market <strong>in</strong> 2016.<br />
M<strong>in</strong>imally <strong>in</strong>vasive glaucoma surgery (<strong>MIGS</strong>) devices are employed <strong>in</strong> the treatment of<br />
glaucoma to provide a safer and less <strong>in</strong>vasive means of reduc<strong>in</strong>g <strong>in</strong>traocular pressure<br />
(IOP) as compared to conventional glaucoma surgery devices. <strong>MIGS</strong> devices are<br />
anticipated to become a preferred surgical modality <strong>in</strong> near future for the treatment of<br />
glaucoma as it reduces dependency on topical medications as well as gets rid of<br />
complications associated to traditional procedures.
Introductionof<br />
<strong>MIGS</strong> <strong>Devices</strong> <strong>Market</strong><br />
Scope of the Report<br />
Key Benefits<br />
Key Audiences
Key Benefits<br />
• The <strong>MIGS</strong> stents generated the highest revenue <strong>in</strong> 2016, and is anticipated to do so<br />
throughout the forecast period, register<strong>in</strong>g a CAGR of 27.1% from 2017 to 2023.<br />
• Eye hospitals dom<strong>in</strong>ated the market, account<strong>in</strong>g for maximum share <strong>in</strong> 2016 and is<br />
expected to witness a CAGR of 26.3% from 2017 to 2023.<br />
• North America dom<strong>in</strong>ated the global m<strong>in</strong>imally <strong>in</strong>vasive glaucoma surgery (<strong>MIGS</strong>)<br />
market, account<strong>in</strong>g for maximum share <strong>in</strong> 2016 and is expected to reta<strong>in</strong> the same<br />
trend dur<strong>in</strong>g 2017 to 2023.<br />
• The <strong>MIGS</strong> shunts product segment is expected to witness the highest growth rate<br />
dur<strong>in</strong>g the forecast period.<br />
• Japan accounted for one-fourth share of the Asia-Pacific m<strong>in</strong>imally <strong>in</strong>vasive<br />
glaucoma surgery (<strong>MIGS</strong>) devices market <strong>in</strong> 2016.
Table of Content (TOC)<br />
Chapter: 1 Introduction<br />
Chapter: 2 Executive Summary<br />
Chapter: 3 <strong>Market</strong> Overview<br />
Chapter: 4 M<strong>in</strong>imally <strong>Invasive</strong> <strong>Glaucoma</strong> <strong>Surgery</strong> (<strong>MIGS</strong>) <strong>Devices</strong> <strong>Market</strong>, By <strong>Surgery</strong><br />
Chapter: 5 M<strong>in</strong>imally <strong>Invasive</strong> <strong>Glaucoma</strong> Target (<strong>MIGS</strong>) <strong>Devices</strong> <strong>Market</strong>, By Target<br />
Chapter: 6 M<strong>in</strong>imally <strong>Invasive</strong> <strong>Glaucoma</strong> Product (<strong>MIGS</strong>) <strong>Devices</strong> <strong>Market</strong>, By Product<br />
Chapter: 7 M<strong>in</strong>imally <strong>Invasive</strong> <strong>Glaucoma</strong> End User (<strong>MIGS</strong>) <strong>Devices</strong> <strong>Market</strong>, By End<br />
User<br />
Chapter: 8 M<strong>in</strong>imally <strong>Invasive</strong> <strong>Glaucoma</strong> <strong>Surgery</strong> (<strong>MIGS</strong>) <strong>Devices</strong> <strong>Market</strong>, By Region
Segments<br />
<strong>MIGS</strong> <strong>Devices</strong> <strong>Market</strong>
Segments<br />
<strong>MIGS</strong> <strong>Devices</strong> <strong>Market</strong>
Segments<br />
<strong>MIGS</strong> <strong>Devices</strong> <strong>Market</strong>
<strong>MIGS</strong> <strong>Devices</strong> <strong>Market</strong><br />
Rise <strong>in</strong> <strong>in</strong>cidence of glaucoma across the globe, reoccurrence<br />
of glaucoma along with other eye disorders, and <strong>in</strong>crease <strong>in</strong><br />
preference for ab <strong>in</strong>terno approach for the treatment of<br />
glaucoma propels the market growth. Geriatric population is<br />
prone to glaucoma such as mild to moderate glaucoma<br />
conditions, primary angle-closure glaucoma, and secondary<br />
angle-closure glaucoma, which is set to drive the growth of<br />
this market. Ineffective drug delivery witnessed <strong>in</strong> the<br />
glaucoma medication has propelled the transition of<br />
glaucoma treatment from medication to m<strong>in</strong>imally <strong>in</strong>vasive<br />
glaucoma surgery (<strong>MIGS</strong>) devices, thereby augment<strong>in</strong>g the<br />
market growth.<br />
Garima Chandra<br />
Research Analyst,<br />
Healthcare at AMR.
Thank You<br />
<strong>MIGS</strong> <strong>Devices</strong> <strong>Market</strong><br />
ThankYou!<br />
For More Details<br />
Do Enquiry<br />
https://www.alliedmarketresearch.com/m<strong>in</strong>imally-<strong>in</strong>vasive-slaucoma-surgery-<strong>MIGS</strong>-devices-market<br />
Follow Us On
Change language